FiercePharma· @FiercePharma · X·· 22 天前AI 评分42
AI 导读
作为一项稳定举措，美国卫生与公众服务部（HHS）已任命 Michael Davis 医学博士、哲学博士和 Karim Mikhail——两人此前分别担任药品审评与研究中心（CDER）和生物制品审评与研究中心（CBER）的代理主任——正式出任各自职位。https://www.fiercepharma.com/pharma/fda-solidifies-cder-cber-leadership-posts-commissioner-confirmation-awaits
正文
In a stabilizing move, the Department of Health and Human Services has tapped Michael Davis, M.D., Ph.D., and Karim Mikhail—who’ve been serving as acting directors of the Centers for Drugs Evaluation and Research (CDER) and the Centers for Biologics Evaluation and Research (CBER), respectively—to occupy their posts on a permanent basis. https://www.fiercepharma.com/pharma/fda-solidifies-cder-cber-leadership-posts-commissioner-confirmation-awaits
来源：FiercePharma · x.com